Host Antitumor Immunity Plays a Role in the Survival of Patients With Newly Diagnosed Triple-Negative Breast Cancer
Menée à partir de l'analyse de 506 échantillons tumoraux prélevés sur 481 patientes atteintes d'un cancer du sein triplement négatif (durée médiane de suivi : 10,6 ans) et incluses dans des essais de phase III évaluant un traitement adjuvant (essai ECOG 2197 ou ECOG 1199), cette étude évalue l'association entre la présence de lymphocytes infiltrant la tumeur et la survie sans maladie, la survie globale ou l'intervalle sans récidive à distance
In the article that accompanies this editorial, Adams et al report on the prognostic value of the presence of tumor-infiltrating lymphocytes (TILs) evaluated on samples from 481 patients with triple-negative breast cancer (TNBC) who were enrolled onto two prospective Eastern Cooperative Oncology Group (ECOG) adjuvant clinical trials (E2197 and E1199). This prospectively defined, retrospective analysis was powered to replicate findings from previous reports, by using the same method of quantification, to confirm that TILs are positively associated with prognosis in primary TNBC...
Journal of Clinical Oncology , éditorial en libre accès, 2014